Growth Metrics

Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (QoQ) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Vanda Pharmaceuticals 379.35 Mn 177.04 Mn 48.56 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 65.64%
Dec 31, 2025 -525.18%
Sep 30, 2025 16.91%
Jun 30, 2025 7.82%
Mar 31, 2025 -504.88%
Dec 31, 2024 8.76%
Sep 30, 2024 -18.28%
Jun 30, 2024 -8.50%
Mar 31, 2024 -74.15%
Dec 31, 2023 -1,845.26%
Sep 30, 2023 -90.82%
Jun 30, 2023 -53.78%
Mar 31, 2023 -52.95%
Dec 31, 2022 110.40%
Sep 30, 2022 25.91%
Jun 30, 2022 140.28%
Mar 31, 2022 -190.84%
Dec 31, 2021 -8.92%
Sep 30, 2021 -19.50%
Jun 30, 2021 11.60%
Mar 31, 2021 5.41%
Dec 31, 2020 37.99%
Sep 30, 2020 -31.56%
Jun 30, 2020 1,687.86%
Mar 31, 2020 -88.52%
Dec 31, 2019 -95.78%
Sep 30, 2019 771.27%
Jun 30, 2019 1,983.33%
Mar 31, 2019 -105.90%
Dec 31, 2018 44.91%
Sep 30, 2018 55.35%
Jun 30, 2018 50.39%
Mar 31, 2018 266.81%
Dec 31, 2017 59.60%
Sep 30, 2017 -196.61%
Jun 30, 2017 79.93%
Mar 31, 2017 -1,429.00%
Dec 31, 2016 -16.28%
Sep 30, 2016 90.69%
Jun 30, 2016 62.63%
Mar 31, 2016 17.02%
Dec 31, 2015 -56.09%
Sep 30, 2015 -74.81%
Jun 30, 2015 46.97%
Mar 31, 2015 -114.77%
Dec 31, 2014 4,913.05%
Sep 30, 2014 93.29%
Jun 30, 2014 18.69%
Mar 31, 2014 -248.07%
Dec 31, 2013 -41.69%
Sep 30, 2013 -59.03%
Jun 30, 2013 25.14%
Mar 31, 2013 -122.22%
Dec 31, 2012 481.94%
Sep 30, 2012 33.48%
Jun 30, 2012 -0.57%
Mar 31, 2012 -44.16%
Dec 31, 2011 -79.67%
Sep 30, 2011 -129.23%
Jun 30, 2011 -1,086.03%
Mar 31, 2011 -95.13%
Dec 31, 2010 -12.34%
Sep 30, 2010 148.75%